Tandem Diabetes Care Inc. (TNDM)
Tandem Diabetes Care (TNDM) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Evaluate the expected performance of Tandem Diabetes Care (TNDM) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Tandem Diabetes Gains 45.7% in a Year: What's Driving the Stock?
TNDM's shares rise as its expanding product portfolio gains market traction. However, the unfavorable macroeconomic scenario is concerning.
Reasons to Retain TNDM Stock in Your Portfolio for Now
A robust diabetes market and several strategic developments raise investors' optimism for Tandem Diabetes.
Tandem Diabetes Forges New R&D Agreement With UVA: Stock to Gain?
TNDM enters a multi-year research collaboration with the UVA Center for Diabetes Technology for the development of AID systems.
TNDM Stock to Gain From t:slim X2 With Dexcom G7 Launch in Canada
Tandem Diabetes' t:slim X2 insulin pump is now compatible with Dexcom G7 CGM in Canada.
Reasons to Retain TNDM Stock in Your Portfolio for Now
Innovations and a robust international market expansion raise investors' optimism for Tandem Diabetes.
TNDM Q3 Earnings Beat, '24 Sales View Up, Stock Falls in Aftermarket
Tandem Diabetes' top and bottom lines outpace estimates in the third quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi.
Tandem Diabetes Care, Inc. (TNDM) Q3 2024 Earnings Conference Call Transcript
Tandem Diabetes Care, Inc. (TNDM) Q3 2024 Earnings Conference Call Transcript
Tandem Diabetes Care (TNDM) Reports Q3 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Tandem Diabetes Care (TNDM) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Tandem Diabetes Care, Inc. (TNDM) Reports Q3 Loss, Tops Revenue Estimates
Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.38 per share a year ago.
Down -21.69% in 4 Weeks, Here's Why Tandem Diabetes Care (TNDM) Looks Ripe for a Turnaround
Tandem Diabetes Care (TNDM) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Why Tandem Diabetes Care Stock Took It on the Chin Tuesday
Flat revenue growth might be in store for the company in a very crucial market.
